title: Daily-diary evaluated side-effects of conformal versus conventional prostatic cancer radiotherapy technique.
abstract: Conventional 4-field box radiotherapy technique induces high morbidity for patients with localized prostatic cancer. Using a patient daily diary, the present study compared side-effects after conventional radiotherapy with conformal radiotherapy for prostate cancer. Fifty-eight patients treated with the conventional technique (with or without sucralfate) were compared with 72 patients treated with conformal technique. The patient groups were compared with an age-matched control population. Patients treated with conformal technique were also evaluated regarding acute and late urinary problems. Results showed that patients treated with conformal technique reported significantly fewer side-effects as compared with conventional technique. Patients treated with sucralfate also showed slightly decreased intestinal morbidity in comparison to non-sucralfate group. Acute and late morbidity evaluated by the patients was decreased after conformal radiotherapy as compared with the conventional technique. Sucralfate may be of value if conformal radiotherapy is used for dose escalation in prostatic cancer patients.
authors.affiliation: Department of Oncology, Umeå University, Sweden. Anders.Widmark@Onkologi.umu.se
authors.forename: A
authors.initials: A
authors.lastname: Widmark
authors.forename: P
authors.initials: P
authors.lastname: Fransson
authors.forename: L
authors.initials: L
authors.lastname: Franzén
authors.forename: B
authors.initials: B
authors.lastname: Littbrand
authors.forename: R
authors.initials: R
authors.lastname: Henriksson
mesh_terms: D015746:Abdominal Pain / Q000209:etiology; D016022:Case-Control Studies; D003672:Defecation / Q000187:drug effects / Q000528:radiation effects; D003967:Diarrhea / Q000209:etiology; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005243:Feces; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006417:Hematuria / Q000209:etiology; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D008499:Medical Records; D009367:Neoplasm Staging; D010146:Pain / Q000209:etiology; D010919:Placebos; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D013392:Sucralfate / Q000008:administration & dosage / Q000627:therapeutic use; D014551:Urinary Tract / Q000528:radiation effects; D014555:Urination Disorders / Q000209:etiology
chemical_list: D005765:Gastrointestinal Agents; D010919:Placebos; D013392:Sucralfate